{
    "clinical_study": {
        "@rank": "13451", 
        "acronym": "EDGE", 
        "arm_group": [
            {
                "arm_group_label": "Continuation Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Alendronate continuation arm"
            }, 
            {
                "arm_group_label": "Discontinuation Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Alendronate discontinuation arm"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a pilot study evaluating the recruitment strategies for sites and patients, data\n      collection instruments, follow-up procedures, administrative processes, and the proposed\n      management strategy for the future large scale national trial. This pilot study is 6 months\n      in length."
        }, 
        "brief_title": "Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.Females 65+\n\n        2.3+ years of alendronate (Fosamax/Binosto) use\n\n        3. Valid social security number\n\n        Exclusion Criteria:\n\n          1. History of any other metabolic bone condition, such as Paget Disease of Bone\n\n          2. Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer.\n\n          3. Has significant underlying illness that would be expected to prevent completion of\n             the study (e.g., life-threatening disease likely to limit survival to less than 3\n             years)?\n\n          4. HIV positive\n\n          5. Involved in a conflicting (investigational drug) clinical trial"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139007", 
            "org_study_id": "F120404006"
        }, 
        "intervention": {
            "arm_group_label": [
                "Continuation Arm", 
                "Discontinuation Arm"
            ], 
            "intervention_name": "Alendronate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Alendronate"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "email": "fosterau@uab.edu", 
                "last_name": "Jeff Foster, MPH", 
                "phone": "205-996-6086"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "University of Alabama at Birmingham"
            }, 
            "investigator": {
                "last_name": "Kenneth G Saag, MD, MsC", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Ability to recruit clinical trial sites for this pilot study.", 
                "measure": "Clinical site recruitment rate", 
                "safety_issue": "No", 
                "time_frame": "6 months following enrollment"
            }, 
            {
                "description": "Rate of participant recruitment into this pilot study.", 
                "measure": "Participant recruitment rate", 
                "safety_issue": "No", 
                "time_frame": "6 months following enrollment"
            }, 
            {
                "description": "Time spent on contracting and initiating sites for this clinical study.", 
                "measure": "Contracting and procedures", 
                "safety_issue": "No", 
                "time_frame": "6 months following enrollment"
            }, 
            {
                "description": "Evaluation of all University of Alabama at Birmingham administrative procedures with this pilot study ie. time to complete contracting, time to complete Institutional Review Board/human subjects training verification for study sites.", 
                "measure": "Administrative procedures", 
                "safety_issue": "No", 
                "time_frame": "6 months following enrollment."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139007"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Via follow-up survey patients will self report diagnoses of osteonecrosis of the jaw.", 
                "measure": "Osteonecrosis of the jaw", 
                "safety_issue": "Yes", 
                "time_frame": "6 months following enrollment"
            }, 
            {
                "description": "Patient reported fracture rate at 6 months after enrollment via survey.", 
                "measure": "Atypical femoral fracture", 
                "safety_issue": "Yes", 
                "time_frame": "6 months following enrollment"
            }, 
            {
                "description": "Patient reported fracture rate at 6 months following enrollment via survey.", 
                "measure": "Clinical fracture rate", 
                "safety_issue": "Yes", 
                "time_frame": "6 months following enrollment"
            }
        ], 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}